Surf Therapeutics reports positive first-in-human data for bioelectronic rheumatoid arthritis treatment — $6M total funding
Summary
Surf Therapeutics reported positive first-in-human data in March 2026 from their bioelectronic medicine approach for rheumatoid arthritis and announced additional financing bringing total funding to $6 million. Surf targets the cholinergic anti-inflammatory pathway — activating the vagal anti-inflammatory reflex using electrical stimulation rather than immunosuppressant drugs — for patients with moderate to severe RA. The first-in-human data is the critical de-risking milestone that demonstrates safety and preliminary feasibility of the bioelectronic approach in humans before controlled efficacy studies.
Why it matters
Surf Therapeutics joining SetPoint Medical in demonstrating first-in-human safety for bioelectronic RA treatment validates the vagal anti-inflammatory pathway as a genuine therapeutic target for rheumatology — not just a research curiosity. The simultaneous pharmacological approach (Nilo Therapeutics targeting the same neural circuits with drugs) and electroceutical approach (Surf with electrical stimulation) creates competitive pressure that will accelerate both tracks toward clinical validation.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial